Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Tesaro	Emergent BioSolutions	Arena Pharmaceuticals	Hutchison China MediTech	Sage Therapeutics
Symbol	NASDAQ:TSRO	NYSE:EBS	NASDAQ:ARNA	NASDAQ:HCM	NASDAQ:SAGE
Price Information
Current Price	$74.96	$60.85	$63.07	$27.09	$72.07
52 Week Range	N/A	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	0.7	2.2	1.7	1.4	1.4
Analysis Score	0.0	3.3	4.5	3.5	3.3
Community Score	2.8	2.7	2.5	2.7	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	1.7	0.0	0.0
Earnings & Valuation Score	0.6	3.1	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	N/A	Buy	Buy	Buy	Buy
Consensus Price Target	N/A	$97.67	$92.00	$40.00	$86.44
% Upside from Price Target	N/A	60.50% upside	45.87% upside	47.66% upside	19.94% upside
Trade Information
Market Cap	$4.13 billion	$3.27 billion	$3.90 billion	$3.96 billion	$4.14 billion
Beta	0.38	1.26	0.83	1.12	2.23
Average Volume	1,970,604	755,439	505,698	233,249	496,505
Sales & Book Value
Annual Revenue	$223.33 million	$1.11 billion	$806.43 million	$204.89 million	$6.87 million
Price / Sales	18.48	2.95	4.74	19.69	612.97
Cashflow	N/A	$2.91 per share	$6.18 per share	N/A	N/A
Price / Cash	N/A	20.89	10.20	N/A	N/A
Book Value	$4.58 per share	$21.08 per share	$21.38 per share	$2.35 per share	$18.23 per share
Price / Book	16.37	2.89	2.95	11.53	3.95
Profitability
Net Income	$-496,120,000.00	$54.50 million	$397.55 million	$-106,020,000.00	$-680,240,000.00
EPS	($9.17)	$2.91	$7.69	($0.80)	($13.38)
Trailing P/E Ratio	N/A	19.57	N/A	N/A	N/A
Forward P/E Ratio	N/A	6.61	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-295.67%	12.50%	N/A	N/A	-7,706.84%
Return on Equity (ROE)	-1,209.72%	26.68%	-33.17%	N/A	-63.81%
Return on Assets (ROA)	-83.34%	12.70%	-30.41%	N/A	-56.64%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.68%	0.04%	0.07%	N/A
Current Ratio	3.40%	3.20%	23.17%	3.14%	11.71%
Quick Ratio	2.83%	2.30%	23.17%	3.01%	11.71%
Ownership Information
Institutional Ownership Percentage	N/A	80.23%	89.67%	33.45%	N/A
Insider Ownership Percentage	33.70%	14.10%	3.05%	N/A	4.80%
Miscellaneous
Employees	N/A	2,200	363	1,280	298
Shares Outstanding	55.05 million	53.59 million	60.59 million	148.90 million	58.43 million
Next Earnings Date	N/A	7/29/2021 (Estimated)	8/4/2021 (Estimated)	N/A	8/9/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Declining Stock and Decent Financials: Is The Market Wrong About Sage Therapeutics, Inc. (NASDAQ:SAGE)? nasdaq.com - May 5 at 6:08 PM
	Sage Therapeutics Inc. (NASDAQ:SAGE) Forecast to gain 41.71% to hit Consensus price target marketingsentinel.com - May 5 at 1:08 PM
	Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms statnews.com - May 5 at 8:07 AM
	Mizuho Securities Stick to Their Hold Rating for SAGE Therapeutics investing.com - May 5 at 1:14 AM
	Sage Therapeutics Breaks Below 200-Day Moving Average - Notable for SAGE nasdaq.com - May 4 at 8:14 PM
	Sage braces for make-or-break depression data biopharmadive.com - May 4 at 3:10 PM
	Sage Therapeutics (NASDAQ:SAGE) Announces Quarterly Earnings Results, Beats Estimates By $0.34 EPS americanbankingnews.com - May 4 at 11:18 AM
	Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress finance.yahoo.com - May 4 at 10:10 AM
	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 4 at 10:10 AM
	Sage Therapeutics, Inc. (NASDAQ:SAGE) Rose 65.85% From Its 52-Week Low; YTD Numbers Fall -8.96% – Here Are Some Things To Keep In Mind marketingsentinel.com - May 1 at 6:46 PM
	4. Biogen/Sage Therapeutics fiercebiotech.com - April 28 at 9:40 AM
	Sage Therapeutics to Present at Upcoming May Investor Conferences finance.yahoo.com - April 28 at 9:40 AM
	Bullish Prospects For Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares In 2021 stocksregister.com - April 26 at 9:09 AM
	Pre-earnings Momentum Trade With a Technical Trigger in Sage Therapeutics Inc cmlviz.com - April 26 at 9:09 AM
	Custom Pre-earnings Bullish Diagonal Trigger in Sage Therapeutics Inc cmlviz.com - April 21 at 1:49 PM
	Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021 finance.yahoo.com - April 20 at 9:22 AM
	SAGE Therapeutics (SAGE) Receives a Hold from Morgan Stanley smarteranalyst.com - April 19 at 7:04 PM
	Morgan Stanley Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $81.00 americanbankingnews.com - April 19 at 1:06 PM
	Analysts Say You Should Go Buying Sage Therapeutics, Inc. (NASDAQ:SAGE) stocksregister.com - April 18 at 8:59 AM
	Is SAGE Stock A Buy or Sell? finance.yahoo.com - April 14 at 3:12 PM
	Sage Therapeutics (NASDAQ:SAGE) Shares Up 8% americanbankingnews.com - April 14 at 1:02 PM
	FY2025 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By Piper Sandler americanbankingnews.com - April 14 at 10:08 AM
	H.C. Wainwright Stick to Their Hold Rating for SAGE Therapeutics investing.com - April 14 at 12:10 AM
	Sage Therapeutics (NASDAQ:SAGE) Stock Price Down 5.6% americanbankingnews.com - April 13 at 3:22 PM
	Sage Therapeutics and Biogen's Phase 2 Study in Essential Tremor Met its Primary Endpoint benzinga.com - April 13 at 9:09 AM
	Sage Therapeutics (NASDAQ:SAGE) Coverage Initiated by Analysts at Piper Sandler marketbeat.com - April 7 at 7:05 AM

Date	Company	Brokerage	Action
12/9/2018	Tesaro	SVB Leerink	Boost Price Target
12/9/2018	Tesaro	Barclays	Downgrade
12/7/2018	Tesaro	HC Wainwright	Downgrade
12/5/2018	Tesaro	Cantor Fitzgerald	Downgrade
12/4/2018	Tesaro	Evercore ISI	Downgrade
12/4/2018	Tesaro	Royal Bank of Canada	Boost Price Target
12/4/2018	Tesaro	Wedbush	Downgrade
12/3/2018	Tesaro	Gabelli	Downgrade
12/3/2018	Tesaro	Guggenheim	Downgrade
12/3/2018	Tesaro	SunTrust Banks	Downgrade
12/3/2018	Tesaro	Robert W. Baird	Set Price Target
12/3/2018	Tesaro	Wells Fargo & Company	Downgrade
11/12/2018	Tesaro	Jefferies Financial Group	Lower Price Target
11/11/2018	Tesaro	Oppenheimer	Set Price Target
11/2/2018	Tesaro	Bank of America	Boost Price Target
11/2/2018	Tesaro	Cowen	Reiterated Rating
5/6/2021	Emergent BioSolutions	Chardan Capital	Lower Price Target
5/5/2021	Emergent BioSolutions	Argus	Downgrade
4/30/2021	Emergent BioSolutions	Benchmark	Lower Price Target
9/14/2020	Emergent BioSolutions	JPMorgan Chase & Co.	Initiated Coverage
5/3/2021	Arena Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
4/19/2021	Arena Pharmaceuticals	Credit Suisse Group	Boost Price Target
4/15/2021	Arena Pharmaceuticals	Needham & Company LLC	Reiterated Rating
3/3/2021	Arena Pharmaceuticals	Jonestrading	Lower Price Target
11/19/2020	Arena Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
2/16/2021	Hutchison China MediTech	Mizuho	Initiated Coverage
10/2/2020	Hutchison China MediTech	Deutsche Bank Aktiengesellschaft	Initiated Coverage
2/20/2020	Hutchison China MediTech	The Goldman Sachs Group	Initiated Coverage
11/19/2019	Hutchison China MediTech	CLSA	Initiated Coverage
7/5/2019	Hutchison China MediTech	Macquarie	Initiated Coverage
3/27/2019	Hutchison China MediTech	HSBC	Initiated Coverage
4/26/2021	Sage Therapeutics	Morgan Stanley	Lower Price Target
4/7/2021	Sage Therapeutics	Piper Sandler	Initiated Coverage
2/1/2021	Sage Therapeutics	Raymond James	Initiated Coverage
1/22/2021	Sage Therapeutics	BMO Capital Markets	Downgrade
12/4/2020	Sage Therapeutics	William Blair	Reiterated Rating
12/1/2020	Sage Therapeutics	Truist	Boost Price Target

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources